Imagin Medical Announces Stock Option Grants
On April 22, 2022, Imagin Medical (CSE: IME, OTCQB: IMEXF) announced the granting of 472,187 stock options to employees, board members, and consultants, within its Stock Option Plan. These options have an exercise price of $0.28 USD per share and are valid for five years, expiring on April 22, 2027. Imagin Medical specializes in surgical imaging, focusing on innovative technologies for visualizing cancer during minimally invasive procedures, with its flagship product being the i/Blue™ Imaging System aimed at improving bladder cancer treatment.
- Granting of 472,187 stock options aligns employee interests with company performance.
- Stock options are priced at $0.28, potentially incentivizing performance.
- None.
VANCOUVER, BC and BOSTON, April 22, 2022 /PRNewswire/ -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) ("Imagin" or the "Company") today announced today that, pursuant to the Company's Stock Option Plan, an aggregate of 472,187 shares have been granted to certain employees, board members and consultants as incentive stock options at an exercise price of
About Imagin Medical
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The Company believes its first product, the i/Blue™ Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of visualizing bladder cancer for better resection. The Company's initial focus is bladder cancer. Learn more at www.imaginmedical.com.
Forward-Looking Statement
Information set forth in this news release contains forward-looking statements. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward- looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company's imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Contacts:
Jim Hutchens, President & CEO
jhutchens@imaginmedical.com
John Vacha, CFO
jvacha@imaginmedical.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/imagin-medical-announces-stock-option-grants-301531159.html
SOURCE Imagin Medical, Inc.
FAQ
What is the purpose of the stock option grant by Imagin Medical announced on April 22, 2022?
What is the exercise price for the stock options granted by Imagin Medical?
How long are the granted stock options valid for Imagin Medical?
What is Imagin Medical's focus in the medical field?
